Search Results For ''

  • Explain Like I’m 5: Trading vs Investing

    If you explore the world of the share market for more than two minutes you’re bound to come across the words “investing” and “trading”. But what is the difference between the two of them and how do you decide which is right for you? Let’s start with the basics. What is trading?  Trading involves frequent

    Read More
    Public
  • Woolworths flags June 24 for Endeavour Group demerger

    Keen eyes have long identified the demerger of Endeavour Group from Woolworths (ASX: WOW) as the most anticipated spinout in years and a date has finally been set which will see Australia’s leading drinks and hospitality group listed on their own.  Operating a drinks business portfolio that includes Dan Murphy’s and BWS as well as

    Read More
    Public
  • Archer Materials are progressing with their chips, not the salt and vinegar kind

    I’m not sure what’s harder- wrapping your head around what Archer Material’s (ASX: AXE) does, or comprehending the value of the market that they are tapping into. A market which currently sits at a whopping USD $400 billion per annum, and is forecast to reach over USD $1 trillion by 2030. Have I got your

    Read More
    Public
  • RentPay launched with target of 200,000 paying customers

    Offering the long-needed solution to a disconnect between tenants, agents and landlords, property tech company Rent.com.au (ASX: RNT) has successfully launched their innovative new platform RentPay which is now available in the Apple and Google app stores. Already with more than 1 million customers using their flagship Rent.com.au website, RentPay takes the tenant experience further

    Read More
    Public
  • Noxopharm receives FDA approval for testing of promising cancer treatment

    Jennie Young was one of the first patients to receive Veyonda, Noxopharm’s (ASX: NOX) proprietary drug. Administered on compassionate grounds, her doctors believe that she responded to it positively. She had leiomyosarcoma, a rare cancer that affects smooth muscle tissue. Soft tissue sarcomas like hers have limited treatment options with only 14% responding to chemotherapy. 

    Read More
    Public
  • Fund Manager Meeting Notes – Temple & Webster (ASX: TPW)

    We recently had a one-on-one meeting with Mr. Mark Tayler, CFO of Temple & Webster Group (TPW). TPW is a pure play online retailer of furniture, homewares, home décor, arts, gifts and lifestyle products. Given we do not cover the stock, the main purpose of this call was to get an initial understanding of the

    Read More
    Public